Express News | The application for once-a-week injection of insulin from Novo Nordisk has not been approved by the US Food and Drug Administration (FDA).
Novo Nordisk Receives Complete Response Letter in the US for Once-weekly Basal Insulin Icodec
Express News | Bernie Sanders, chairman of the Senate Health Committee, said it is now possible to lower the price of weight loss drugs at novo-nordisk a/s; currently focused on novo-nordisk a/s, but will definitely pay attention to eli lilly and co in the future.
Express News | Bernie Sanders, Chairman of the U.S. Senate Committee on Health, believes that Novo-Nordisk (NVO.N) may reduce the price of weight-loss drugs. He is currently focusing on Novo-Nordisk, but will definitely pay attention to Eli Lilly and Co. (LLY.N) in the
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
An analysis of U.S. pharmacy claims data reveals that only one in four patients prescribed Novo Nordisk A/S's (NYSE:NVO) weight-loss drugs, Wegovy and Ozempic, continue their treatment after two
Novo Nordisk's (NVO.US) expensive weight-loss drug: three-quarters of people give up after taking it for two years.
According to an analysis report on American drugstore statements obtained by foreign media revealed by the Wisdom Financial APP, only a quarter of American patients taking Wegovy or Ozempic from novo-nordisk a/s (NVO.US) were still taking these drugs after two years. The analysis also shows that the use of these drugs has been steadily declining over time. The analysis report does not include details of the reasons why patients discontinue taking these drugs, but it does provide a longer-term perspective on the true experience of patients taking drugs, rather than previous studies lasting over one year or shorter. There is evidence that many patients may
"Weight-loss miracle drugs" discounting growth space? Research found that 75% of patients stopped taking the medicines within two years.
Research has found that only a few patients can adhere to long-term use of GLP-1 weight loss drugs, and the huge potential for growth of "miracle weight loss drugs" may have to be discounted.
Most Patients Discontinue Novo's Wegovy, Ozempic Within Two Years: Report
Express News | Novo Nordisk's weight-loss miracle drug faces new challenges: only one quarter of patients adhere to the medication for two years.
Market Chatter: Analysis Shows Use of Novo Nordisk's Wegovy, Ozempic for Weight Loss Declines After Two Years
An analysis of US pharmacy claims provided to Reuters showed most patients stop using Novo Nordisk's (NVO) Wegovy or Ozempic after two years, Reuters reported.The analysis conducted by Prime
Most Patients Stop Using Wegovy, Ozempic for Weight Loss Within Two Years, Analysis Finds
Counterfeit diabetes drug sellers will face charges in an Austrian court.
On July 10th, Glon Hui | Austrian prosecutors announced that they will bring criminal charges against two men who are accused of selling counterfeit Novo Nordisk diabetes drug Ozempic, which has caused harm to three women. The first hearing of the case is scheduled for September 16th. The Austrian health and safety agency BASG said in October last year that several people were hospitalized after using fake Ozempic, which was the first report of harm to users after Europe stepped up its crackdown on counterfeiters. The agency said at the time that the symptoms of the victims (including hypoglycemia) were consistent with insulin poisoning.
TOP 20 trading volume | Tesla has risen for ten consecutive days, with the stock price hitting a new high in almost six months and trading nearly $42 billion.
Nvidia, ranked second, closed up 2.48% with a trading volume of $36.713 billion. KeyBanc analyst John Vinh raised Nvidia's target price from $130 to $180. Apple, ranked third, rose 0.38% to a new historical high, with a trading volume of $10.987 billion and a market cap of over $3.5 trillion.
US stocks closed with the S&P hitting a new high. Tesla rose for the tenth consecutive day, while Nvidia rose nearly 2.5%.
Apple, Applied Materials, and Eli Lilly and Co's stock prices hit new highs again; China concept stocks are generally up, with Baidu up more than 8%.
FTC Chair Khan Slams PBMs for Higher Drug Prices in an Interim Report on the Industry
Eli Lilly Awaits Head-to-head Study on GLP-1s After New Report Reaffirms Superiority
A new study has reaffirmed that Eli Lilly's (LLY) GLP-1 drugs fare better for weight loss than Novo Nordisk's (NVO).
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
Hot Research: Lilly's Mounjaro Beats Novo's Ozempic in Weight Loss, Study Says. The Stocks Battle It Out. -- Barrons.com
(The companies mentioned in Hot Research are subjects of research reports issued recently by investment firms. Their opinions do not represent those of Barrons.com or Dow Jones & Company, Inc. Some
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were trending lower late Tuesday morning, declining 0.73% to 1,439.07 on the S&P Europe Select ADR Index.From continental Europe,
On Mounjaro, Patients Lose Weight Faster Than on Ozempic: Study